B
Brett E. Fortune
Researcher at Cornell University
Publications - 98
Citations - 1573
Brett E. Fortune is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Liver transplantation. The author has an hindex of 17, co-authored 70 publications receiving 936 citations. Previous affiliations of Brett E. Fortune include Yale University & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City.
Kaveh Hajifathalian,Sonal Kumar,Carolyn Newberry,Shawn L. Shah,Brett E. Fortune,Tibor Krisko,Shiara Ortiz-Pujols,Xi Kathy Zhou,Andrew J. Dannenberg,Rekha B. Kumar,Reem Z. Sharaiha +10 more
TL;DR: It is hypothesized that the presence of obesity may play a role in the clinical course of patients with COVID‐19, a rapidly expanding global pandemic in which patients exhibit a wide spectrum of disease severity.
Journal ArticleDOI
Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications.
Kaveh Hajifathalian,Tibor Krisko,Amit Mehta,Sonal Kumar,Robert E. Schwartz,Brett E. Fortune,Reem Z. Sharaiha,Alyson Kaplan,Susana Gonzalez,Daniel Skaf,Bryan Ang,Anthony J. Choi,Angela Wong,Aiya Aboubakr,Rachel Niec,Elizabeth Rohan,Julia Speiser,Xiaohan Ying,Yushan Pan,Mallory Ianelli,Anjana Rajan,Arjun Ravishankar,Sunena Tewani,Enad Dawod,Qais Dawod,Russell Rosenblatt,David L. Carr-Locke,Shawn L. Shah,Srihari Mahadev,David Wan,Carl V. Crawford,Evan Sholle,Robert S. Brown,David Cohen +33 more
Journal ArticleDOI
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
Dana J. Lukin,Anand Kumar,Kaveh Hajifathalian,Reem Z. Sharaiha,Ellen Scherl,Randy S. Longman,Randy S. Longman,Gabriela Funez-dePagnier,Lucia Duenas-Bianchi,Vinita Jacob,Robert Battat,Tibor I. Krisko,Brett E. Fortune +12 more
Journal ArticleDOI
Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival.
Vinay Sundaram,Shannon Kogachi,Robert J. Wong,Constantine J. Karvellas,Brett E. Fortune,Nadim Mahmud,Josh Levitsky,Robert S. Rahimi,Rajiv Jalan +8 more
TL;DR: Improvement of ACLF-3 at listing to ACLF 0-2 at transplantation enhances post-LT survival, particularly in recipients who are older than age 60, who were removed from the mechanical ventilator, or who recovered from circulatory or brain failure.
Journal ArticleDOI
Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients
Vinay Sundaram,Parth D. Shah,Robert J. Wong,Constantine J. Karvellas,Brett E. Fortune,Nadim Mahmud,Alexander Kuo,Rajiv Jalan +7 more
TL;DR: Patients listed for liver transplantation as status 1a currently receive the highest priority on the waiting list, but the presence of acute on chronic liver failure with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score.